Supplemental Figure 3 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors

Tumor mutational burden and diagnosed Lynch syndrome in patients with MSI-high status determined by only one method</p

Supplemental Figure 2 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors

Kaplan Meier curves for progression-free survival according to the unsupervised clusters and the line of immune checkpoint inhibitor</p

Supplemental Figure 4 from Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors

Heatmap with unsupervised clustering in the validation cohort</p